JP2016513094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513094A5 JP2016513094A5 JP2015556574A JP2015556574A JP2016513094A5 JP 2016513094 A5 JP2016513094 A5 JP 2016513094A5 JP 2015556574 A JP2015556574 A JP 2015556574A JP 2015556574 A JP2015556574 A JP 2015556574A JP 2016513094 A5 JP2016513094 A5 JP 2016513094A5
- Authority
- JP
- Japan
- Prior art keywords
- dll3
- cancer
- fragments
- level
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1302447.6 | 2013-02-12 | ||
| GBGB1302447.6A GB201302447D0 (en) | 2013-02-12 | 2013-02-12 | Therapeutic and diagnostic target |
| PCT/GB2014/050407 WO2014125273A1 (en) | 2013-02-12 | 2014-02-12 | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513094A JP2016513094A (ja) | 2016-05-12 |
| JP2016513094A5 true JP2016513094A5 (enExample) | 2017-03-16 |
| JP6654046B2 JP6654046B2 (ja) | 2020-02-26 |
Family
ID=47998983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556574A Active JP6654046B2 (ja) | 2013-02-12 | 2014-02-12 | Ｄｌｌ３結合試薬を含む治療薬及び診断薬の癌標的 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160032006A1 (enExample) |
| EP (2) | EP3736293A1 (enExample) |
| JP (1) | JP6654046B2 (enExample) |
| KR (1) | KR102167550B1 (enExample) |
| CN (1) | CN105143266B (enExample) |
| AU (1) | AU2014217611B2 (enExample) |
| CA (1) | CA2900134A1 (enExample) |
| CL (1) | CL2015002223A1 (enExample) |
| DK (1) | DK2956483T3 (enExample) |
| EA (1) | EA034182B1 (enExample) |
| ES (1) | ES2813360T3 (enExample) |
| GB (1) | GB201302447D0 (enExample) |
| HU (1) | HUE050828T2 (enExample) |
| IL (1) | IL239983B (enExample) |
| MX (1) | MX370597B (enExample) |
| PH (1) | PH12015501744A1 (enExample) |
| PL (1) | PL2956483T3 (enExample) |
| WO (1) | WO2014125273A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014138474A (ru) | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| RU2016111137A (ru) * | 2013-08-28 | 2017-10-03 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Сконструированные конъюгаты против dll3 и способы применения |
| PE20160674A1 (es) | 2013-08-28 | 2016-07-21 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones |
| WO2015127407A1 (en) | 2014-02-21 | 2015-08-27 | Stemcentrx, Inc. | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| WO2016016415A1 (en) * | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
| JP6749312B2 (ja) | 2014-07-31 | 2020-09-02 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ | 最適化された種間特異的二重特異性単鎖抗体コンストラクト |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA039325B1 (ru) * | 2016-02-03 | 2022-01-13 | Эмджен Рисерч (Мюник) Гмбх | Конструкции биспецифических антител, связывающиеся с дпб3 (dll3) и кд3 (cd3) |
| CA3011942A1 (en) | 2016-02-03 | 2017-08-10 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| AU2018280871B2 (en) | 2017-06-08 | 2024-09-26 | Black Belt Therapeutics Ltd | CD38 modulating antibody |
| WO2019034752A1 (en) | 2017-08-16 | 2019-02-21 | Tusk Therapeutics Ltd | Cd38 modulating antibody |
| EP3668543A1 (en) | 2017-08-16 | 2020-06-24 | Black Belt Therapeutics Limited | Cd38 antibody |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| SI3694529T1 (sl) | 2017-10-13 | 2024-10-30 | Harpoon Therapeutics, Inc. | Trispecifične beljakovine in načini uporabe |
| EP3720963A4 (en) | 2017-12-05 | 2021-12-08 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137 |
| EP3732195A4 (en) | 2017-12-28 | 2022-02-09 | Chugai Seiyaku Kabushiki Kaisha | CYTOTOXICITY-INDUCING THERAPEUTIC |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| IL277863B2 (en) | 2018-04-11 | 2026-02-01 | Inhibrx Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| CN110412179A (zh) * | 2018-04-26 | 2019-11-05 | 缪荣明 | 一种液相色谱检测颗粒酶a的方法 |
| WO2019217145A1 (en) | 2018-05-08 | 2019-11-14 | Phanes Therapeutics, Inc. | Anti-dll3 antibodies and uses thereof |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CA3105891A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| CN113260634A (zh) | 2018-09-28 | 2021-08-13 | 中外制药株式会社 | 包含改变的抗体可变区的抗原结合分子 |
| EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| WO2020182517A1 (en) * | 2019-03-08 | 2020-09-17 | Oncolab Diagnostics Gmbh | Cancer diagnosis and prognosis |
| US20220184127A1 (en) * | 2019-04-08 | 2022-06-16 | Phanes Therapeutics, Inc. | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Monodomain antibodies of cd28 and their multivalent and multispecific constructs |
| KR20220162690A (ko) * | 2020-01-31 | 2022-12-08 | 젠선 바이오파마, 인코포레이티드 | 이중특이성 t 세포 관여항체 |
| US12486331B2 (en) | 2020-01-31 | 2025-12-02 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| CA3173587A1 (en) * | 2020-03-31 | 2021-10-07 | Chugai Seiyaku Kabushiki-Kaisha | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
| AU2022217274A1 (en) * | 2021-02-05 | 2023-07-27 | Phanes Therapeutics, Inc. | Bispecific antibodies with charge pairs and uses thereof |
| CR20240135A (es) * | 2021-09-17 | 2024-05-17 | Wuxi Biologics Ireland Ltd | Moléculas de unión a d3 y usos de estas |
| EP4519294A1 (en) * | 2022-05-04 | 2025-03-12 | Earli Inc. | Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells |
| TW202530259A (zh) * | 2023-09-21 | 2025-08-01 | 大陸商樂普創一生物科技（上海）有限公司 | 抗ｄｌｌ３抗體及其用途 |
| WO2025163082A1 (en) * | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025190281A1 (en) * | 2024-03-11 | 2025-09-18 | Lepu Biopharma Co., Ltd. | Anti-dll3 antibodies and uses thereof |
| CN120168667B (zh) * | 2025-03-18 | 2026-04-14 | 中国科学院近代物理研究所 | 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用 |
| CN119841904A (zh) * | 2025-03-18 | 2025-04-18 | 中国科学院近代物理研究所 | 一种dll3亲和肽及其应用 |
| CN120536580B (zh) * | 2025-06-10 | 2026-03-06 | 复旦大学附属妇产科医院 | Dll3作为宫颈神经内分泌癌治疗靶点及其应用 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| AU622426B2 (en) | 1987-12-11 | 1992-04-09 | Abbott Laboratories | Assay using template-dependent nucleic acid probe reorganization |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| GB9106048D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccines |
| AU8874591A (en) | 1990-10-22 | 1992-05-20 | Abbott Laboratories | Stabilized anoxic diagnostic reagent solution |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| AU662148B2 (en) | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| JP3949712B2 (ja) | 1991-12-02 | 2007-07-25 | メディカル リサーチ カウンシル | 抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| CA2148252C (en) | 1992-10-30 | 2007-06-12 | Roger Brent | Interaction trap system for isolating novel proteins |
| US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| PT744958E (pt) | 1994-01-31 | 2003-11-28 | Univ Boston | Bancos de anticorpos policlonais |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| GB9608510D0 (en) | 1996-04-25 | 1996-07-03 | Medical Res Council | Calcium dependent binding ligands |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
| US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| EP1600459A3 (en) | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP2006523090A (ja) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
| US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| EP1824796A4 (en) | 2004-11-16 | 2010-02-17 | Avidia Res Inst | PROTEIN SKELETONS AND USES THEREOF |
| CA2595682A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| JP2008539753A (ja) | 2005-05-09 | 2008-11-20 | グリクアート バイオテクノロジー アクチェンゲゼルシャフト | 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子 |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CA2633593A1 (en) * | 2005-12-16 | 2007-10-04 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
| EP2216339A1 (en) | 2006-01-16 | 2010-08-11 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
| US7862813B2 (en) * | 2006-07-29 | 2011-01-04 | Bjork Jr Robert Lamar | Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug |
| SG10201808730VA (en) | 2007-04-03 | 2018-11-29 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
| EP2235055A2 (en) | 2007-12-24 | 2010-10-06 | Oxford Biotherapeutics Ltd. | Ephrin type-a receptor 10 protein |
| AU2009235467A1 (en) * | 2008-04-07 | 2009-10-15 | Ablynx Nv | Single variable domains against the Notch pathways |
| CA2729602A1 (en) | 2008-07-08 | 2010-01-14 | Oncomed Pharmaceuticals, Inc. | Notch1 receptor binding agents and methods of use thereof |
| SG10201405434VA (en) | 2009-09-18 | 2014-10-30 | Amgen Res Munich Gmbh | Dosage regimen for administering an epcamxcd3 bispecific antibody |
| EP3907242A1 (en) * | 2010-01-29 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
| US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| US9587021B2 (en) | 2011-05-21 | 2017-03-07 | Macrogenics, Inc. | CD3-binding molecules capable of binding to human and non-human CD3 |
| US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
| RU2014138474A (ru) * | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
-
2013
- 2013-02-12 GB GBGB1302447.6A patent/GB201302447D0/en not_active Ceased
-
2014
- 2014-02-12 EA EA201500835A patent/EA034182B1/ru not_active IP Right Cessation
- 2014-02-12 EP EP20175944.6A patent/EP3736293A1/en not_active Withdrawn
- 2014-02-12 ES ES14705561T patent/ES2813360T3/es active Active
- 2014-02-12 AU AU2014217611A patent/AU2014217611B2/en not_active Ceased
- 2014-02-12 EP EP14705561.0A patent/EP2956483B1/en not_active Revoked
- 2014-02-12 KR KR1020157024805A patent/KR102167550B1/ko not_active Expired - Fee Related
- 2014-02-12 WO PCT/GB2014/050407 patent/WO2014125273A1/en not_active Ceased
- 2014-02-12 CN CN201480020452.4A patent/CN105143266B/zh active Active
- 2014-02-12 HU HUE14705561A patent/HUE050828T2/hu unknown
- 2014-02-12 MX MX2015010372A patent/MX370597B/es active IP Right Grant
- 2014-02-12 JP JP2015556574A patent/JP6654046B2/ja active Active
- 2014-02-12 DK DK14705561.0T patent/DK2956483T3/da active
- 2014-02-12 PL PL14705561T patent/PL2956483T3/pl unknown
- 2014-02-12 CA CA2900134A patent/CA2900134A1/en not_active Abandoned
- 2014-02-12 US US14/766,992 patent/US20160032006A1/en not_active Abandoned
-
2015
- 2015-07-16 IL IL239983A patent/IL239983B/en active IP Right Grant
- 2015-08-07 CL CL2015002223A patent/CL2015002223A1/es unknown
- 2015-08-07 PH PH12015501744A patent/PH12015501744A1/en unknown
-
2018
- 2018-03-07 US US15/914,432 patent/US20180201691A1/en not_active Abandoned
-
2020
- 2020-11-20 US US16/953,459 patent/US20210079114A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bahadır et al. | Applications of electrochemical immunosensors for early clinical diagnostics | |
| JP2016500110A5 (enExample) | ||
| Cabral et al. | Procalcitonin for the early diagnosis of sepsis in burn patients: a retrospective study | |
| EP4282405A3 (en) | Detection of cancer biomarkers using nanoparticles | |
| CY1122871T1 (el) | Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 | |
| Kofla-Dłubacz et al. | Metalloproteinase-3 and-9 as novel markers in the evaluation of ulcerative colitis activity in children | |
| EA201070738A1 (ru) | Композиции и способы детекции tiab | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| JP2016511823A5 (enExample) | ||
| WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
| WO2013068374A3 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment | |
| WO2017025617A8 (en) | Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers | |
| JP2016536012A5 (enExample) | ||
| WO2014036495A3 (en) | Diagnostic assays and kits for detection of folate receptor 1 | |
| Bahadır et al. | Biosensor technologies for analyses of food contaminants | |
| WO2013068373A3 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment | |
| RU2015102194A (ru) | Способы лечения связанных с fgfr3 состояний | |
| JP2014521089A5 (enExample) | ||
| JP2015210268A5 (enExample) | ||
| WO2012012802A3 (en) | Neoepitope detection of disease using protein arrays | |
| JP2017505897A5 (enExample) | ||
| Schlaeger et al. | Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval? | |
| Zhang et al. | Prognostic significance of combining VEGFA, FLT1 and KDR mRNA expression in lung cancer | |
| WO2008089135A3 (en) | Identification of biomarkers predictive of dasatinib effects in cancer cells | |
| Pillai et al. | Biomarker panel for early screening of trastuzumab-induced cardiotoxicity among breast cancer patients in west virginia |